Stock Track | Tandem Diabetes Care Soars 22.83% Intraday on Strong Q4 Earnings Beat and BofA Upgrade

Stock Track

Yesterday

Tandem Diabetes Care's stock soared 22.83% during intraday trading on Friday, driven by better-than-expected fourth-quarter financial results and a significant analyst upgrade.

The diabetes technology company reported a Q4 net loss of $0.01 per diluted share, which was much better than the $0.09 per share loss anticipated by analysts. Quarterly sales reached $290.4 million, surpassing the $277 million consensus estimate. The company also provided full-year 2026 sales guidance in the range of approximately $1.07 billion to $1.09 billion.

Adding to the positive sentiment, BofA Securities upgraded Tandem Diabetes Care to Neutral from Underperform and more than doubled its price target to $30 from $15. The upgrade reflects improved confidence in the company's financial performance and outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141957529"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141957529\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141957529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141957529","market":"nz","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Soars 22.83% Intraday on Strong Q4 Earnings Beat and BofA Upgrade","media":"Stock Track","content":"<p>Tandem Diabetes Care's stock soared 22.83% during intraday trading on Friday, driven by better-than-expected fourth-quarter financial results and a significant analyst upgrade.</p><p>The diabetes technology company reported a Q4 net loss of $0.01 per diluted share, which was much better than the $0.09 per share loss anticipated by analysts. Quarterly sales reached $290.4 million, surpassing the $277 million consensus estimate. The company also provided full-year 2026 sales guidance in the range of approximately $1.07 billion to $1.09 billion.</p><p>Adding to the positive sentiment, BofA Securities upgraded Tandem Diabetes Care to Neutral from Underperform and more than doubled its price target to $30 from $15. The upgrade reflects improved confidence in the company's financial performance and outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Soars 22.83% Intraday on Strong Q4 Earnings Beat and BofA Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Soars 22.83% Intraday on Strong Q4 Earnings Beat and BofA Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tandem Diabetes Care's stock soared 22.83% during intraday trading on Friday, driven by better-than-expected fourth-quarter financial results and a significant analyst upgrade.</p><p>The diabetes technology company reported a Q4 net loss of $0.01 per diluted share, which was much better than the $0.09 per share loss anticipated by analysts. Quarterly sales reached $290.4 million, surpassing the $277 million consensus estimate. The company also provided full-year 2026 sales guidance in the range of approximately $1.07 billion to $1.09 billion.</p><p>Adding to the positive sentiment, BofA Securities upgraded Tandem Diabetes Care to Neutral from Underperform and more than doubled its price target to $30 from $15. The upgrade reflects improved confidence in the company's financial performance and outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1141957529","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141957529","pubTimestamp":1771598099,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tandem Diabetes Care's stock soared 22.83% during intraday trading on Friday, driven by better-than-expected fourth-quarter financial results and a significant analyst upgrade.The diabetes technology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"股票追踪|Tandem Diabetes Care盘中飙升22.83%，因第四季度盈利强劲增长和美国银行升级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Tandem Diabetes Care's stock soared 22.83% during intraday trading on Friday, driven by better-than-expected fourth-quarter financial results and a significant analyst upgrade.The diabetes technology company reported a Q4 net loss of $0.01 per diluted share, which was much better than the $0.09 per share loss anticipated by analysts. Quarterly sales reached $290.4 million, surpassing the $277 million consensus estimate. The company also provided full-year 2026 sales guidance in the range of approximately $1.07 billion to $1.09 billion.Adding to the positive sentiment, BofA Securities upgraded Tandem Diabetes Care to Neutral from Underperform and more than doubled its price target to $30 from $15. The upgrade reflects improved confidence in the company's financial performance and outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}